Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

Objective: The HepatAssist liver support system is an extracorporeal porcine hepatocyte-
based bioartificial liver (BAL). The safety and efficacy of the BAL were evaluated in a …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Prospective measurements were made of serum C‐reactive protein levels and erythrocyte
sedimentation rate in sixty‐four patients with Crohn's disease and fifty with ulcerative colitis …

Background The assessment of treatment response in idiopathic pulmonary fibrosis (IPF) is
complicated by the variable clinical course. We examined the variability in the rate of …

This post hoc analysis examined the differences in idiopathic pulmonary fibrosis disease
progression and the effects of pirfenidone in patients stratified by more preserved versus …

Serum amyloid-A protein (SAA) is the putative precursor of amyloid-A (AA) protein which
forms the fibrils in reactive systemic or secondary amyloidosis. By means of a novel …

Background Pirfenidone is an oral antifibrotic agent that has been shown to reduce the
decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an …

Abstract In the United Kingdom and United States of America, fulminant viral hepatitis is due
mainly to sporadic (non-parenteral non-A, non-B hepatitis and hepatitis B whereas that …

Intrahepatic cholestasis of pregnancy (IHCP) is the most common liver disorder unique to
pregnancy and is second only to viral hepatitis as a cause of jaundice. 34, 35, 67,117 …